Background: Membrane αKlotho (hereinafter called Klotho) is highly expressed in the kidney and functions as a coreceptor of FGF receptors (FGFRs) to activate specific fibroblast growth factor 23 (FGF23) signal pathway. FGF23 is produced in bones and participates in the maintenance of mineral homeostasis. The extracellular domain of transmembrane Klotho can be cleaved by secretases and released into the circulation as soluble Klotho. Soluble Klotho does not only weakly activate FGFRs to transduce the FGF23 signaling pathway, but also functions as an enzyme and hormonal substance to play a variety of biological functions. FGF23 exerts its biological effects through activation of FGFRs in a Klotho-dependent manner. However, extremely high FGF23 can exert its pathological action in a Klotho-independent manner. Summary: The decline in serum and urinary Klotho followed by a rise in serum FGF23 at an early stage of chronic kidney disease (CKD) functions as an early biomarker for kidney dysfunction and can also serve as a predictor for risk of cardiovascular disease (CVD) and mortality in both CKD patients and the general population. Moreover, Klotho deficiency is a pathogenic factor for CKD progression and CVD. FGF23 may also contribute to CVD. Prevention of Klotho decline, reactivation of endogenous Klotho production, or supplementation of exogenous Klotho attenuate renal fibrosis, retard CKD progression, improve mineral metabolism, ameliorate cardiomyopathy, and alleviate vascular calcification in CKD. However, the poor CVD outcome after depletion of FGF23 with FGF23 antibody stimulates the generation of a more specific inhibitor of FGF23 for CKD treatment. Key Message: Klotho/FGF23 may not only be diagnostic and/or prognostic biomarkers for CKD and CVD, but are also pathogenic contributors to CKD progression and CVD development. The Klotho/FGF23 axis should be a novel target for renal clinics.

Keywords:
Biomarker, Cardiovascular disease, Chronic kidney disease, FGF23, Klotho
1.
Kuro-o M, Matsumura Y, Aizawa H, et al: Mutation of the mouse klotho gene leads to a syndrome resembling ageing. Nature 1997;390:45-51.
2.
Ito S, Kinoshita S, Shiraishi N, et al: Molecular cloning and expression analyses of mouse betaklotho, which encodes a novel Klotho family protein. Mech Dev 2000;98:115-119.
3.
Ito S, Fujimori T, Hayashizaki Y, et al: Identification of a novel mouse membrane-bound family 1 glycosidase-like protein, which carries an atypical active site structure. Biochim Biophys Acta 2002;1576:341-345.
4.
Hu MC, Shiizaki K, Kuro-o M, et al: Fibroblast growth factor 23 and Klotho: physiology and pathophysiology of an endocrine network of mineral metabolism. Annu Rev Physiol 2013;75:503-533.
5.
Hu MC, Shi M, Zhang J, et al: Renal production, uptake, and handling of circulating αKlotho. J Am Soc Nephrol 2016;27:79-90.
6.
Chen CD, Tung TY, Liang J, et al: Identification of cleavage sites leading to the shed form of the anti-aging protein klotho. Biochemistry 2014;53:5579-5587.
7.
Matsumura Y, Aizawa H, Shiraki-Iida T, et al: Identification of the human klotho gene and its two transcripts encoding membrane and secreted klotho protein. Biochem Biophys Res Commun 1998;242:626-630.
8.
Chen CD, Li H, Liang J, et al: The anti-aging and tumor suppressor protein klotho enhances differentiation of a human oligodendrocytic hybrid cell line. J Mol Neurosci 2015;55:76-90.
9.
Semba RD, Moghekar AR, Hu J, et al: Klotho in the cerebrospinal fluid of adults with and without Alzheimer's disease. Neurosci Lett 2014;558:37-40.
10.
Akimoto T, Yoshizawa H, Watanabe Y, et al: Characteristics of urinary and serum soluble Klotho protein in patients with different degrees of chronic kidney disease. BMC Nephrol 2012;13:155.
11.
Lau WL, Leaf EM, Hu MC, et al: Vitamin D receptor agonists increase klotho and osteopontin while decreasing aortic calcification in mice with chronic kidney disease fed a high phosphate diet. Kidney Int 2012;82:1261-1270.
12.
Hu MC, Shi M, Zhang J, et al: Klotho deficiency is an early biomarker of renal ischemia-reperfusion injury and its replacement is protective. Kidney Int 2010;78:1240-1251.
13.
Hu MC, Shi M, Zhang J, et al: Klotho: a novel phosphaturic substance acting as an autocrine enzyme in the renal proximal tubule. FASEB J 2010;24:3438-3450.
14.
Hu MC, Shi M, Zhang J, et al: Klotho deficiency causes vascular calcification in chronic kidney disease. J Am Soc Nephrol 2011;22:124-136.
15.
Hu MC, Kuro-o M, Moe OW: Renal and extrarenal actions of Klotho. Semin Nephrol 2013;33:118-129.
16.
Hu MC, Shi M, Cho HJ, et al: Klotho and phosphate are modulators of pathologic uremic cardiac remodeling. J Am Soc Nephrol 2015;26:1290-1302.
17.
Panesso MC, Shi M, Cho HJ, et al: Klotho has dual protective effects on cisplatin-induced acute kidney injury. Kidney Int 2014;85:855-870.
18.
ADHR Consortium: Autosomal dominant hypophosphataemic rickets is associated with mutations in FGF23. Nat Genet 2000;26:345-348.
19.
Gattineni J, Baum M: Regulation of phosphate transport by fibroblast growth factor 23 (FGF23): implications for disorders of phosphate metabolism. Pediatr Nephrol 2010;25:591-601.
20.
Krajisnik T, Bjorklund P, Marsell R, et al: Fibroblast growth factor-23 regulates parathyroid hormone and 1alpha-hydroxylase expression in cultured bovine parathyroid cells. J Endocrinol 2007;195:125-131.
21.
Bian A, Xing C, Hu MC: Alpha Klotho and phosphate homeostasis. J Endocrinol Invest 2014;37:1121-1126.
22.
Kuro-o M: Klotho, phosphate and FGF-23 in ageing and disturbed mineral metabolism. Nat Rev Nephrol 2013;9:650-660.
23.
Myrvang H: Basic research: role of renal Klotho in mineral metabolism. Nat Rev Nephrol 2012;8:553.
24.
Huang CL, Moe OW: Klotho: a novel regulator of calcium and phosphorus homeostasis. Pflugers Arch 2011;462:185-193.
25.
Gutierrez OM: Fibroblast growth factor 23 and disordered vitamin D metabolism in chronic kidney disease: updating the ‘‘trade-off'' hypothesis. Clin J Am Soc Nephrol 2010;5:1710-1716.
26.
Scholze A, Liu Y, Pedersen L, et al: Soluble α-klotho and its relation to kidney function and fibroblast growth factor-23. J Clin Endocrinol Metab 2014;99:E855-E861.
27.
Stenvinkel P, Larsson TE: Chronic kidney disease: a clinical model of premature aging. Am J Kidney Dis 2013;62:339-351.
28.
Kooman JP, Broers NJ, Usvyat L, et al: Out of control: accelerated aging in uremia. Nephrol Dial Transplant 2013;28:48-54.
29.
Foley RN, Parfrey PS, Sarnak MJ: Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis 1998;32(5 suppl 3):S112-S119.
30.
Ide N, Olauson H, Sato T, et al: In vivo evidence for a limited role of proximal tubular Klotho in renal phosphate handling. Kidney Int 2016;90:348-362.
31.
Mitobe M, Yoshida T, Sugiura H, et al: Oxidative stress decreases klotho expression in a mouse kidney cell line. Nephron Exp Nephrol 2005;101:e67-e74.
32.
Fliser D, Seiler S, Heine GH, et al: Measurement of serum soluble Klotho levels in CKD 5D patients: useful tool or dispensable biomarker? Nephrol Dial Transplant 2012;27:1702-1703.
33.
Kim HR, Nam BY, Kim DW, et al: Circulating α-klotho levels in CKD and relationship to progression. Am J Kidney Dis 2013;61:899-909.
34.
Kitagawa M, Sugiyama H, Morinaga H, et al: A decreased level of serum soluble Klotho is an independent biomarker associated with arterial stiffness in patients with chronic kidney disease. PLoS One 2013;8:e56695.
35.
Goetz R, Nakada Y, Hu MC, et al: Isolated C-terminal tail of FGF23 alleviates hypophosphatemia by inhibiting FGF23-FGFR-Klotho complex formation. Proc Natl Acad Sci USA 2010;107:407-412.
36.
Suzuki M, Uehara Y, Motomura-Matsuzaka K, et al: betaKlotho is required for fibroblast growth factor (FGF) 21 signaling through FGF receptor (FGFR) 1c and FGFR3c. Mol Endocrinol 2008;22:1006-1014.
37.
Masuyama R, Stockmans I, Torrekens S, et al: Vitamin D receptor in chondrocytes promotes osteoclastogenesis and regulates FGF23 production in osteoblasts. J Clin Invest 2006;116:3150-3159.
38.
Farrow EG, Yu X, Summers LJ, et al: Iron deficiency drives an autosomal dominant hypophosphatemic rickets (ADHR) phenotype in fibroblast growth factor-23 (Fgf23) knock-in mice. Proc Natl Acad Sci USA 2011;108: E1146-E1155.
39.
Shimada T, Mizutani S, Muto T, et al: Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia. Proc Natl Acad Sci USA 2001;98:6500-6505.
40.
Fukagawa M, Kazama JJ: With or without the kidney: the role of FGF23 in CKD. Nephrol Dial Transplant 2005;20:1295-1298.
41.
Kurosu H, Ogawa Y, Miyoshi M, et al: Regulation of fibroblast growth factor-23 signaling by klotho. J Biol Chem 2006;281:6120-6123.
42.
Urakawa I, Yamazaki Y, Shimada T, et al: Klotho converts canonical FGF receptor into a specific receptor for FGF23. Nature 2006;444:770-774.
43.
Six I, Okazaki H, Gross P, et al: Direct, acute effects of Klotho and FGF23 on vascular smooth muscle and endothelium. PLoS One 2014;9:e93423.
44.
Faul C, Amaral AP, Oskouei B, et al: FGF23 induces left ventricular hypertrophy. J Clin Invest 2011;121:4393-4408.
45.
Grabner A, Faul C: The role of fibroblast growth factor 23 and Klotho in uremic cardiomyopathy. Curr Opin Nephrol Hypertens 2016;25:314-324.
46.
Di Marco GS, Reuter S, Kentrup D, et al: Treatment of established left ventricular hypertrophy with fibroblast growth factor receptor blockade in an animal model of CKD. Nephrol Dial Transplant 2014;29:2028-2035.
47.
Eckardt KU, Coresh J, Devuyst O, et al: Evolving importance of kidney disease: from subspecialty to global health burden. Lancet 2013;382:158-169.
48.
Levey AS, de Jong PE, Coresh J, et al: The definition, classification, and prognosis of chronic kidney disease: a KDIGO Controversies Conference report. Kidney Int 2011;80:17-28.
49.
Barker SL, Pastor J, Carranza D, et al: The demonstration of αKlotho deficiency in human chronic kidney disease with a novel synthetic antibody. Nephrol Dial Transplant 2015;30:223-233.
50.
Koh N, Fujimori T, Nishiguchi S, et al: Severely reduced production of klotho in human chronic renal failure kidney. Biochem Biophys Res Commun 2001;280:1015-1020.
51.
Asai O, Nakatani K, Tanaka T, et al: Decreased renal α-Klotho expression in early diabetic nephropathy in humans and mice and its possible role in urinary calcium excretion. Kidney Int 2012;81:539-547.
52.
Sakan H, Nakatani K, Asai O, et al: Reduced renal α-Klotho expression in CKD patients and its effect on renal phosphate handling and vitamin D metabolism. PLoS One 2014;9:e86301.
53.
Pavik I, Jaeger P, Ebner L, et al: Secreted Klotho and FGF23 in chronic kidney disease stage 1 to 5: a sequence suggested from a cross-sectional study. Nephrol Dial Transplant 2013;28:352-359.
54.
Cano FJ, Freundlich M, Ceballos ML, et al: Longitudinal FGF23 and Klotho axis characterization in children treated with chronic peritoneal dialysis. Clin Kidney J 2014;7:457-463.
55.
Xie J, Yoon J, An SW, et al: Soluble Klotho protects against uremic cardiomyopathy independently of fibroblast growth factor 23 and phosphate. J Am Soc Nephrol 2015;26:1150-1160.
56.
Seiler S, Rogacev KS, Roth HJ, et al: Associations of FGF-23 and sKlotho with cardiovascular outcomes among patients with CKD stages 2-4. Clin J Am Soc Nephrol 2014;9:1049-1058.
57.
Park MY, Herrmann SM, Saad A, et al: Biomarkers of kidney injury and klotho in patients with atherosclerotic renovascular disease. Clin J Am Soc Nephrol 2015;10:443-451.
58.
Devaraj S, Syed B, Chien A, et al: Validation of an immunoassay for soluble Klotho protein: decreased levels in diabetes and increased levels in chronic kidney disease. Am J Clin Pathol 2012;137:479-485.
59.
Desjardins L, Liabeuf S, Renard C, et al: FGF23 is independently associated with vascular calcification but not bone mineral density in patients at various CKD stages. Osteoporos Int 2012;23:2017-2025.
60.
Portale AA, Wolf M, Juppner H, et al: Disordered FGF23 and mineral metabolism in children with CKD. Clin J Am Soc Nephrol 2014;9:344-353.
61.
Chudek J, Kocelak P, Owczarek A, et al: Fibroblast growth factor 23 (FGF23) and early chronic kidney disease in the elderly. Nephrol Dial Transplant 2014;29:1757-1763.
62.
Fliser D, Kollerits B, Neyer U, et al: Fibroblast growth factor 23 (FGF23) predicts progression of chronic kidney disease: the Mild to Moderate Kidney Disease (MMKD) Study. J Am Soc Nephrol 2007;18:2600-2608.
63.
Chathoth S, Al-Mueilo S, Cyrus C, et al: Elevated fibroblast growth factor 23 concentration: prediction of mortality among chronic kidney disease patients. Cardiorenal Med 2015;6:73-82.
64.
Zhang M, Yan J, Zhu M, et al: Fibroblast growth factor 23 predicts coronary calcification and poor prognosis in patients with chronic kidney disease stages 3-5D. Ann Clin Lab Sci 2015;45:17-22.
65.
Arnlov J, Carlsson AC, Sundstrom J, et al: Serum FGF23 and risk of cardiovascular events in relation to mineral metabolism and cardiovascular pathology. Clin J Am Soc Nephrol 2013;8:781-786.
66.
Silswal N, Touchberry CD, Daniel DR, et al: FGF23 directly impairs endothelium-dependent vasorelaxation by increasing superoxide levels and reducing nitric oxide bioavailability. Am J Physiol Endocrinol Metab 2014;307:E426-E436.
67.
Shah NH, Dong C, Elkind MS, et al: Fibroblast growth factor 23 is associated with carotid plaque presence and area: the Northern Manhattan Study. Arterioscler Thromb Vasc Biol 2015;35:2048-2053.
68.
Gutierrez OM, Mannstadt M, Isakova T, et al: Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N Engl J Med 2008;359:584-592.
69.
Ix JH, Katz R, Kestenbaum BR, et al: Fibroblast growth factor-23 and death, heart failure, and cardiovascular events in community-living individuals: CHS (Cardiovascular Health Study). J Am Coll Cardiol 2012;60:200-207.
70.
Sarmento-Dias M, Santos-Araujo C, Poinhos R, et al: Fibroblast growth factor 23 is associated with left ventricular hypertrophy, not with uremic vasculopathy in peritoneal dialysis patients. Clin Nephrol 2016;85:135-141.
71.
Mirza MA, Larsson A, Melhus H, et al: Serum intact FGF23 associate with left ventricular mass, hypertrophy and geometry in an elderly population. Atherosclerosis 2009;207:546-551.
72.
Faul C: Fibroblast growth factor 23 and the heart. Curr Opin Nephrol Hypertens 2012;21:369-375.
73.
Grabner A, Amaral AP, Schramm K, et al: Activation of cardiac fibroblast growth factor receptor 4 causes left ventricular hypertrophy. Cell Metab 2015;22:1020-1032.
74.
Smith ER: The use of fibroblast growth factor 23 testing in patients with kidney disease. Clin J Am Soc Nephrol 2014;9:1283-1303.
75.
Smith ER, Cai MM, McMahon LP, et al: Biological variability of plasma intact and C-terminal FGF23 measurements. J Clin Endocrinol Metab 2012;97:3357-3365.
76.
Amatschek S, Haller M, Oberbauer R: Renal phosphate handling in human - what can we learn from hereditary hypophosphataemias? Eur J Clin Invest 2010;40:552-560.
77.
Shimada T, Urakawa I, Isakova T, et al: Circulating fibroblast growth factor 23 in patients with end-stage renal disease treated by peritoneal dialysis is intact and biologically active. J Clin Endocrinol Metab 2010;95:578-585.
78.
Goebel S, Lienau J, Rammoser U, et al: FGF23 is a putative marker for bone healing and regeneration. J Orthop Res 2009;27:1141-1146.
79.
Lindberg K, Amin R, Moe OW, et al: The kidney is the principal organ mediating klotho effects. J Am Soc Nephrol 2014;25:2169-2175.
80.
Shi M, Flores B, Gillings N, et al: αKlotho mitigates progression of AKI to CKD through activation of autophagy. J Am Soc Nephrol 2016;27:2331-2345.
81.
Chen J, Zhang X, Zhang H, et al: Elevated Klotho promoter methylation is associated with severity of chronic kidney disease. PLoS One 2013;8:e79856.
82.
Young GH, Wu VC: KLOTHO methylation is linked to uremic toxins and chronic kidney disease. Kidney Int 2012;81:611-612.
83.
Rubinek T, Shulman M, Israeli S, et al: Epigenetic silencing of the tumor suppressor klotho in human breast cancer. Breast Cancer Res Treat 2012;133:649-657.
84.
Moreno JA, Izquierdo MC, Sanchez-Nino MD, et al: The inflammatory cytokines TWEAK and TNFα reduce renal Klotho expression through NFκB. J Am Soc Nephrol 2011;22:1315-1325.
85.
Mehi SJ, Maltare A, Abraham CR, et al: MicroRNA-339 and microRNA-556 regulate Klotho expression in vitro. Age (Dordr) 2014;36:141-149.
86.
Kang WL, Xu GS: Atrasentan increased the expression of klotho by mediating miR-199b-5p and prevented renal tubular injury in diabetic nephropathy. Sci Rep 2016;6:19979.
87.
Yang HC, Deleuze S, Zuo Y, et al: The PPARgamma agonist pioglitazone ameliorates aging-related progressive renal injury. J Am Soc Nephrol 2009;20:2380-2388.
88.
Yoon HE, Ghee JY, Piao S, et al: Angiotensin II blockade upregulates the expression of Klotho, the anti-ageing gene, in an experimental model of chronic cyclosporine nephropathy. Nephrol Dial Transplant 2011;26:800-813.
89.
Narumiya H, Sasaki S, Kuwahara N, et al: HMG-CoA reductase inhibitors up-regulate anti-aging klotho mRNA via RhoA inactivation in IMCD3 cells. Cardiovasc Res 2004;64:331-336.
90.
Ritter CS, Zhang S, Delmez J, et al: Differential expression and regulation of Klotho by paricalcitol in the kidney, parathyroid, and aorta of uremic rats. Kidney Int 2015;87:1141-1152.
91.
Hu MC: Klotho connects intermedin1-53 to suppression of vascular calcification in chronic kidney disease. Kidney Int 2016;89:534-537.
92.
Doi S, Zou Y, Togao O, et al: Klotho inhibits transforming growth factor-beta1 (TGF-beta1) signaling and suppresses renal fibrosis and cancer metastasis in mice. J Biol Chem 2011;286:8655-8665.
93.
Isakova T, Ix JH, Sprague SM, et al: Rationale and approaches to phosphate and fibroblast growth factor 23 reduction in CKD. J Am Soc Nephrol 2015;26:2328-2339.
94.
Adema AY, de Jong MA, de Borst MH, et al: Phosphate binding therapy to lower serum fibroblast-growth-factor-23 concentrations in chronic kidney disease: rationale and study design of the Sevelamer on FGF23 Trial (SoFT). Nephron 2016, Epub ahead of print.
95.
Spatz C, Roe K, Lehman E, et al: Effect of a non-calcium-based phosphate binder on fibroblast growth factor 23 in chronic kidney disease. Nephron Clin Pract 2013;123:61-66.
96.
Soriano S, Ojeda R, Rodriguez M, et al: The effect of phosphate binders, calcium and lanthanum carbonate on FGF23 levels in chronic kidney disease patients. Clin Nephrol 2013;80:17-22.
97.
Goto S, Nakai K, Kono K, et al: Dietary phosphorus restriction by a standard low-protein diet decreased serum fibroblast growth factor 23 levels in patients with early and advanced stage chronic kidney disease. Clin Exp Nephrol 2014;18:925-931.
98.
Shalhoub V, Ward SC, Sun B, et al: Fibroblast growth factor 23 (FGF23) and alpha-Klotho stimulate osteoblastic MC3T3.E1 cell proliferation and inhibit mineralization. Calcif Tissue Int 2011;89:140-150.
99.
Sun N, Guo Y, Liu W, et al: FGF23 neutralization improves bone quality and osseointegration of titanium implants in chronic kidney disease mice. Sci Rep 2015;5:8304.
100.
Ketteler M, Biggar PH, Liangos O: FGF23 antagonism: the thin line between adaptation and maladaptation in chronic kidney disease. Nephrol Dial Transplant 2013;28:821-825.
101.
Razzaque MS, Lanske B: Hypervitaminosis D and premature aging: lessons learned from Fgf23 and Klotho mutant mice. Trends Mol Med 2006;12:298-305.
© 2016 S. Karger AG, Basel
2016
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.